BioArctic announces that the Phase 2b study of BAN2401 in early Alzheimer´s Disease continues toward 18 month endpoint December 21, 2017 13:00 Regulatory Read more
BioArctic presents Nomination Committee and publishes financial calendar 2018 November 9, 2017 13:30 Regulatory Read more
Change in the number of shares and votes in BioArctic AB (publ) October 31, 2017 18:00 Regulatory Read more
BioArctic’s patent for its product candidate antibody BAN0805, for Parkinson’s disease, is now granted in Europe October 13, 2017 10:15 Regulatory Read more
